Genscript Biotech Corporation (HKG:1548)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 29.60B |
| Revenue (ttm) | 7.47B |
| Net Income (ttm) | -4.15B |
| Shares Out | 2.19B |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | 43.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,736,900 |
| Average Volume | 9,852,154 |
| Open | 13.53 |
| Previous Close | 13.53 |
| Day's Range | 13.45 - 13.76 |
| 52-Week Range | 9.95 - 19.40 |
| Beta | 0.91 |
| RSI | 59.89 |
| Earnings Date | Mar 15, 2026 |
About Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Bio... [Read more]
News
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Perfor...
Genscript Biotech Earnings Call Transcript: H2 2025
Revenue surged 61.4% year-over-year to $959.5 million, with adjusted net profit up 285% to $230.3 million. All segments grew, driven by global expansion, AI-powered innovation, and strong productization, while non-cash losses from Legend Biotech impacted reported net income.
Genscript Biotech Earnings Call Transcript: H1 2025
Revenue grew 81.9% year-over-year to $519 million, with all segments expanding and adjusted profit from continuing operations reaching $178 million. ProBio saw a 511% revenue jump, driven by Lenovo payments, while Life Science and Bestzyme posted steady growth. Strong cash reserves and global expansion support continued investment and margin resilience.
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J. , Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a...
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
PISCATAWAY, N.J. , July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG ra...
GenScript Biotech Corporation Reports FY 2024 Results
Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J.
Genscript Biotech Earnings Call Transcript: H2 2024
Revenue grew 6.1% to $590M, with strong Life Science and Bestzyme growth offsetting ProBio's decline. A $3.2B one-time gain from Legend Biotech deconsolidation drove net profit, while 2025 guidance targets double-digit growth for all segments and stable margins.
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
LONDON , Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech G...
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J. , Nov. 10, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations ...
Genscript Biotech Earnings Call Transcript: H1 2024
Revenue rose 43.5% YoY to $561.4M, led by Legend's 156% growth from Carvykti. Life Science and Bestzyme showed solid gains, while ProBio faced headwinds but is recovering. Guidance remains positive for H2, with strong cash positions and ongoing capacity expansions.
GenScript Biotech Reports First Half 2024 Results
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development Impressive Financial Growth: The group reported a 43.5% increase in revenue, d...
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
PISCATAWAY, N.J. , June 18, 2024 /PRNewswire/ -- GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to ...
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties
Shares of GenScript Biotech plunged in Hong Kong amid concerns that the company could face U.S. scrutiny due to alleged ties with the Chinese government.
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
The U.S. House of Representatives committee on China has asked the FBI and the intelligence community for a briefing on GenScript Biotechnology Co and three subsidiaries to determine if the Chinese Co...
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
GenScript continues to build on its fast and dependable in vitro transcription RNA synthesis service, offering a new self-amplifying RNA format that enhances the potency and efficacy of vaccines, immu...
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
SAN FRANCISCO--(BUSINESS WIRE)-- #manufacturing--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Co...
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 ...
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment
PISCATAWAY, N.J. , April 15, 2024 /PRNewswire/ -- On April 15, GenScript Biotech Corporation ("GenScript"), a world's leading technology and service provider of life science R&D and manufacture, annou...
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance
PISCATAWAY, N.J. , March 26, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that it has been awarded the Bronze Medal by the ...
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
R&D Innovation to Lead the Future, Deepening Customer Value Creation Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and sta...
Genscript Biotech Earnings Call Transcript: H2 2023
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
SAN FRANCISCO , Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco. The J.P. Morgan Healthcare Conference has bee...
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
NANJING, China , Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference in San Franci...
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
NANJING, China , Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. Howev...
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
NANJING, China , Dec. 7, 2023 /PRNewswire/ -- The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagina...